We are live on ! Find out more
VERV

Verve Therapeutics
VERV

Delisted

VERV was delisted on the 24th of July, 2025.

Back to rankings

6 hedge funds and large institutions have $1.24M invested in Verve Therapeutics in 2025 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 169 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 1

81.59% less ownership

Funds ownership: 81.84% → 0.26% (-82%)

97% less funds holding

Funds holding: 175 → 6 (-169)

100% less capital invested

Capital invested by funds: $819M → $1.24M (-$818M)

100% less funds holding in top 10

Funds holding in top 10: 3 → 0 (-3)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 169

Holders
6
Holders Change
-169
Holders Change %
-96.57%
% of All Funds
0.08%
Holding in Top 10
–
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
2
Reduced
1
Closed
169
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
XT
XTX Topco
Cayman Islands
+$955K
2
IA
IFP Advisors
Florida
+$4.29K

Top Sellers

Rank Fund Capital Flow
1
AI
Alphabet Inc
California
-$137M
2
BlackRock
BlackRock
New York
-$82.6M
3
PCM
Pentwater Capital Management
Florida
-$75.5M
4
Vanguard Group
Vanguard Group
Pennsylvania
-$47.1M
5
CC
Casdin Capital
New York
-$46M
Name Holding Trade Value Shares
Change 		Change in
Stake
Nordea Investment Management
26
Nordea Investment Management
Sweden
– -$7.62M -675,849 Closed
Charles Schwab
27
Charles Schwab
California
– -$6.65M -592,436 Closed
Northern Trust
28
Northern Trust
Illinois
– -$6.61M -588,830 Closed
BNP Paribas Financial Markets
29
BNP Paribas Financial Markets
France
– -$6.36M -566,204 Closed
WAM
30
Weiss Asset Management
Massachusetts
– -$6.05M -538,422 Closed
Morgan Stanley
31
Morgan Stanley
New York
– -$5.7M -507,127 Closed
Bank of America
32
Bank of America
North Carolina
– -$5.46M -485,803 Closed
ACM
33
ADAR1 Capital Management
Texas
– -$5.27M -469,018 Closed
Two Sigma Advisers
34
Two Sigma Advisers
New York
– -$4.28M -381,300 Closed
OAC
35
OMERS Administration Corp
Ontario, Canada
– -$4.17M -371,200 Closed
WIC
36
Water Island Capital
New York
– -$3.77M -335,593 Closed
NCM
37
Nantahala Capital Management
Connecticut
– -$3.72M -331,437 Closed
GCIA
38
Gabelli & Co Investment Advisers
New York
– -$3.4M -302,400 Closed
Barclays
39
Barclays
United Kingdom
– -$3.39M -301,599 Closed
Wellington Management Group
40
Wellington Management Group
Massachusetts
– -$3.35M -298,688 Closed
Citadel Advisors
41
Citadel Advisors
Florida
– -$3.23M -288,004 Closed
GF
42
Gabelli Funds
New York
– -$3M -267,520 Closed
TI
43
Trexquant Investment
Connecticut
– -$2.58M -229,781 Closed
Bank of New York Mellon
44
Bank of New York Mellon
New York
– -$2.48M -220,788 Closed
AA
45
AQR Arbitrage
Connecticut
– -$2.34M -208,700 Closed
Jane Street
46
Jane Street
New York
– -$2.23M -198,657 Closed
UBS AM
47
UBS AM
Illinois
– -$2.06M -183,610 Closed
Citigroup
48
Citigroup
New York
– -$1.98M -176,556 Closed
SSA
49
Schonfeld Strategic Advisors
New York
– -$1.98M -176,281 Closed
AQR Capital Management
50
AQR Capital Management
Connecticut
– -$1.93M -171,820 Closed
1
2
3 4 5

VERV Hedge Fund Activity: Q3 2025 in Review

6 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Verve Therapeutics (VERV) for Q3 2025, worth a combined $1.24M — down 100% from $819M a quarter earlier.

Sellers outnumbered buyers: 169 funds closed out of VERV and 0 opened new positions — a net loss of 169 holders — while 1 trimmed existing stakes and 2 added.

The largest buyer was XTX Topco, adding an estimated $955K. The largest seller was Alphabet Inc, exiting entirely with an estimated $137M sold.

  • 6 institutional investors held Verve Therapeutics (VERV) as of Q3 2025, down from 175 in Q2 2025.
  • Funds reported $1.24M of Verve Therapeutics stock for Q3 2025, down 100% quarter-over-quarter.
  • 0 funds opened new Verve Therapeutics positions in Q3 2025 and 169 closed out, a net change of -169 holders.
  • The largest Verve Therapeutics buyer in Q3 2025 was XTX Topco, an estimated $955K added.
  • The largest Verve Therapeutics seller in Q3 2025 was Alphabet Inc, an estimated $137M sold.

Based on aggregated 13F filings for Q3 2025.